Company intelligence / Profile preview

OS Animal Health

New York, New York, USA

Ownership: Private
Development stage: Other

Overview

OST-HER2 demonstrated statistically significant increase in overall survival in canine osteosarcoma (historical conditional approval data); recent clinical evidence shows prevention of amputation and control of metastatic disease

Therapeutic areas: Oncology
Modalities: ImmunotherapyRecombinant proteinBiologic
Industry: Veterinary

Partnerships

Collaborations with animal health advisors

Beyond the preview

Go deeper on OS Animal Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OS Animal Health.

Explore the full profile